OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Moses on Recent Trials in mHSPC

December 7th 2019

Kelvin Alexander Moses, MD, PhD, discusses recent trials in metastatic hormone-sensitive prostate cancer.

Dr. Oh on Remaining Challenges in mHSPC

December 7th 2019

William K. Oh, MD, discusses remaining challenges in metastatic hormone-sensitive prostate cancer.

Dr. Grande on the Rationale of the IMvigor130 Trial in Urothelial Cancer

December 7th 2019

Enrique Grande, MD, discusses the rationale of the IMvigor130 trial in urothelial cancer.

Dr. Rule on Potential for CAR T-Cell Therapy in MCL

December 7th 2019

Simon Rule, MD, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma.

Dr. Gerson on Updates in Relapsed/Refractory MCL

December 6th 2019

James N. Gerson, MD, discusses recent updates in relapsed/refractory mantle cell lymphoma.

Dr. Shah on Improving the Benefit of Immunotherapy in Gastric/GEJ Cancer

December 6th 2019

Manish A. Shah, MD, discusses ongoing efforts to improve immunotherapy in gastric and gastroesophageal junction cancer.

Dr. Voss on Phase I/II Trial Data of MEDI0680/Durvalumab Versus Nivolumab in mRCC

December 6th 2019

Martin H. Voss, MD, discusses results of a randomized phase I/II trial looking at the combination of MEDI0680 and durvalumab (Imfinzi) versus nivolumab (Opdivo) in metastatic renal cell carcinoma.

Next Steps for Wnt Research in Colorectal Cancer

December 6th 2019

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

Dr. Wierda on Chemoimmunotherapy in CLL

December 6th 2019

William G. Wierda, MD, PhD, discusses the use of chemoimmunotherapy in treating patients with chronic lymphocytic leukemia.

Dr. Hidalgo Medina on Treatment Considerations in Pancreatic Cancer

December 5th 2019

Manuel Hidalgo Medina, MD, PhD, discusses treatment considerations in pancreatic cancer.

Dr. Singh on Potential Implications of the IMvigor130 Trial in Bladder Cancer

December 5th 2019

Parminder Singh, MD, discusses potential implications of the phase III IMvigor130 trial in advanced bladder cancer.

Dr. Corcoran on Promising Combination Strategies With Immunotherapy in mCRC

December 5th 2019

Ryan B. Corcoran, MD, PhD, discusses promising combination strategies with immunotherapy in metastatic colorectal cancer.

Dr. McBride on the Potential of Biosimilars in Oncology

December 5th 2019

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses the potential utility of biosimilars in oncology.

Dr. Mailankody on BCMA CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

December 5th 2019

Sham Mailankody, MBBS, discusses research regarding the BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma.

Dr. Daud on Dabrafenib/Trametinib Vs Immunotherapy in Melanoma

December 5th 2019

Adil Daud, MD, discusses the combination of dabrafenib and trametinib versus immunotherapy in patients with BRAF V600-mutant metastatic melanoma.

Dr. Goy on Treating Older Patients With MCL

December 5th 2019

Andre Goy, MD, MS, discusses treatment approaches for older patients with mantle cell lymphoma.

Dr. Hudson on the Utility of Liquid Biopsy in Metastatic Lung Cancer

December 5th 2019

Kathryn E. Hudson, MD, discusses the utility of liquid biopsies in metastatic lung cancer.

Dr. Vidal on Choosing Between Available Trastuzumab Biosimilars

December 4th 2019

Gregory Vidal, MD, PhD, discusses how the field will determine which trastuzumab (Herceptin) biosimilar to prescribe in clinical practice.

Dr. Crafton on Secondary Surgical Cytoreduction in Ovarian Cancer

December 4th 2019

Sarah Crafton, MD, gynecologic oncologist, Allegheny Health Network, discusses secondary surgical cytoreduction in recurrent ovarian cancer.

Dr. Ocean on Impact of the PRODIGE 24/CCTG PA.6 Trial in Pancreatic Cancer

December 3rd 2019

Allyson Ocean, MD, discusses the impact of the phase III PRODIGE 24/CCTG PA.6 trial on patients with pancreatic cancer.